Tresiba FlexTouch - Injection Insulin Degludec - 100IU/ml 1 3ml Pen(s) / 3ml Pen Novo Nordisk Introduction: Tresiba FlexTouch is an ultra long-acting type of insulin used to treat types 1 and 2 diabetes mellitus in both adults and children. It provides a steady level of insulin in the body for an entire day and helps control blood sugar levels. This helps to prevent complications of diabetes. Tresiba FlexTouch can be prescribed by itself or along with a fast-acting type of insulin or other diabetes medicines. Your doctor or nurse will teach you the correct way of injecting it under the skin. You should use this medicine regularly as per the dose advised to get the most... Uses of Tresiba FlexTouch: Diabetes mellitus (Type 1 & Type 2) Side effects of Tresiba FlexTouch: Hypoglycemia (low blood glucose level)Injection site allergic reactionLipodystrophy (skin thickening or pits at the injection site) How to use Tresiba FlexTouch: Your doctor or nurse will guide you how to use this medicine. How Tresiba FlexTouch works: Tresiba FlexTouch is a long-acting insulin that provides consistent, all-day sugar control. It works like your body's natural insulin. Insulin facilitates reuptake of sugar in muscle and fat cells and also suppresses the production of sugar in the liver. What if you forget to take Tresiba FlexTouch?: If you miss a dose of Tresiba FlexTouch take it as soon as you remember. Do not take two doses of Tresiba FlexTouch within 8 hours of each other. Indication: Diabetes Mellitus Administration: Inject SC once daily at any time of day Inject SC into the thigh, upper arm, or abdomen Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy Do not administer IV, IM, or in an insulin infusion pump Adult Dose: Adult: S/C: Insulin Degludec is ultra long-acting basal insulin for once-daily at any time of the day, preferably at the same time every day. Initiation: Patients with type 2 diabetes mellitus: The recommended daily starting dose is 10 units followed by individual dosage adjustments. Patients with type 1 diabetes mellitus: One third to one half of the total daily insulin dose; as a general rule, 0.2-0.4 units/kg can be used to calculate the initial total daily insulin dose in insulin-naïve patients with type 1 diabetes Insulin Degludec is to be used once-daily with meal-time insulin and requires subsequent individual dosage... Child Dose: Safety and efficacy not established Contraindication: Hypersensitivity to the active substance or to any of the excipients.Hypoglycaemia, Hyperglycaemia, Eye disorder. Mode of Action: Once-daily basal insulin analogue Insulin and its analogues lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production; insulin inhibits lipolysis and proteolysis and enhances protein synthesis; targets include skeletal muscle, liver, and adipose tissue Precaution: Insulin Degludecs must not be injected into a vein (intravenously) or a muscle (intramuscularly) and must not be used in infusion pumps. There is no experience with Insulin Degludec in children and adolescents under 18 years of age. Lactation: Unknown if distributed in human breast milk Side Effect: >10% Nasopharyngitis (12.9-23.9%),Severe hypoglycemic episode (0.3-12.3%),Upper respiratory tract infection (8.4-11.9%),Headache (8.8-11.8%) 1-10% Diarrhea (6.3%),Sinusitis (5.1%),Gastroenteritis (5.1%),Injection site reactions (3.8%),Peripheral edema (0.9-3%) <1% Lipodystrophy Interaction: Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.